# A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li

Source: https://onco.cc/trials/nct04524871/  
OnCo record `nct04524871` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Atezolizumab, Bevacizumab, Tiragolumab in hepatocellular carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) is a phase 1/2 interventional study registered as NCT04524871 by Hoffmann-La Roche, with 518 participants planned, started 2020-11-01 and due to reach its primary completion in 2027-07-30. Interventions recorded: Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120. Conditions listed: Advanced Liver Cancers. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04524871
- Phase: 1/2
- Setting: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- Sponsor: Hoffmann-La Roche
- Enrolled: 518

## Sources

- ClinicalTrials.gov NCT04524871: https://clinicaltrials.gov/study/NCT04524871

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [ADG126](https://onco.cc/drugs/adg126/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Tiragolumab](https://onco.cc/drugs/tiragolumab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct04524871.json